Immune T-cells of the CAR T-cell therapy CT103A are able to rapidly eliminate disease-driving immune cells and reduce immune cells’ overall inflammatory activity in people with neuromyelitis optica spectrum disorder (NMOSD), a study shows. “This study is the first in-depth single-cell … analysis of multiple types of body fluids…
CT103A CAR T-cells
The CAR T-cell therapy CT103A appears safe generally and may ease disability and improve the quality of life in adults with relapsed or refractory neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against aquaporin-4 (AQP4), according to data from a small Phase 1 clinical trial. “In this…
Recent Posts
- Early trial of experimental CAR T-cell therapy seeks people with NMOSD
- Because patients are the reason for the research, we deserve a seat at the table
- Disability in NMOSD patients may worsen even without relapses
- Aging with NMOSD: How I’m facing the future with hope
- Smoking hinders NMOSD relapse recovery, review study shows